Trials / Completed
CompletedNCT02509624
Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib in participants with impaired hepatic function relative to matched, healthy controls.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selonsertib | 6 mg tablets administered orally in fed state |
Timeline
- Start date
- 2015-08-18
- Primary completion
- 2015-12-15
- Completion
- 2015-12-15
- First posted
- 2015-07-28
- Last updated
- 2021-01-27
- Results posted
- 2021-01-27
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02509624. Inclusion in this directory is not an endorsement.